Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Young women with breast cancer more likely to respond to neoadjuvant chemotherapy

SABCS 2012

Published: 6 Dec 2012

Views: 3838

Rating:

Save

Prof Sibylle Loibl - University of Frankfurt, Frankfurt, Germany

Women with breast cancer aged 35 or younger were more likely than older women to achieve a pathological complete response after neoadjuvant chemotherapy, according to data presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium.

Read more in ecancernews.

Related Videos

Low-dose olanzapine after highly emetogenic chemotherapy can be the new...

Dr Jyoti Bajpai - Tata Memorial Centre, Mumbai, India

Low-dose olanzapine after highly emetogenic chemotherapy can be the new standard of care for solid tumours ( Dr Jyoti Bajpai - Tata Memorial Centre, Mumbai, India )

Dr Nita Nair - Apollo Cancer Centres, Mumbai

Breast Cancer ( Dr Nita Nair - Apollo Cancer Centres, Mumbai )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

Updates on HR-positive HER2-negative breast cancer

Dr Mariana Chavez - MD Anderson Cancer Center, Houston, USA

Updates on HR-positive HER2-negative breast cancer ( Dr Mariana Chavez - MD Anderson Cancer Center, Houston, USA )

Updates on triple-negative breast cancer and immunotherapy

Dr Avan Armaghani - Moffitt Cancer Center, Tampa, USA

Updates on triple-negative breast cancer and immunotherapy ( Dr Avan Armaghani - Moffitt Cancer Center, Tampa, USA )

ASCO 2023: Breast cancer research highlights

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

ASCO 2023: Breast cancer research highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

Nine-weeks trastuzumab still effective compared with one year trastuzumab for...

Prof Pierfranco Conte - Istituto Oncologico Veneto, Padova, Italy

Nine-weeks trastuzumab still effective compared with one year trastuzumab for early-stage HER2 positive breast cancer ( Prof Pierfranco Conte - Istituto Oncologico Veneto, Padova, Italy )

Neo-adjuvant therapy for different cancers in the Philippines

Dr Priscilla Caguioa - St Luke's Medical Center, Manila, Philippines

Neo-adjuvant therapy for different cancers in the Philippines ( Dr Priscilla Caguioa - St Luke's Medical Center, Manila, Philippines )

More from ecancer